Hill January 11, 2024
Joseph Choi

Despite receiving reports of patients experiencing suicidal ideation last year, the Food and Drug Administration (FDA) said it has not found a link between this side effect and the class of diabetes drugs that includes Ozempic, Mounjaro and Zepbound.

The FDA received reports in 2023 of patients experiencing suicidal ideation, hair loss and aspiration — an obstruction of the airway — after taking GLP-1 agonists, a category of drugs that treats diabetes and obesity by mimicking a naturally-occurring hormone.

These side effects were not listed on the medication guides for popular GLP-1 agonists, leading the FDA to open an inquiry into whether further regulation was needed for these types of drugs.

“Our preliminary evaluation has not found evidence that use...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech, Provider
MHE Week in Review – New PBM Reform Bill, Cardiac Diseases Cost
Deep learning uncovers gene targets and potential drugs to slow brain aging
FDA issues flu vaccine recommendations: 5 respiratory updates
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
HIMSSCast: The 'genetic revolution' is underway

Share This Article